The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
ASAP CRN Competitive Renewal Opportunity, 2024Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
Study Rationale: Many people with Parkinson’s disease (PD) develop untreatable cognitive symptoms due to changes in the brain’s cerebral cortex. These symptoms, which include problems with attention...
-
Research Grant, 2024Planning for a Dynamic Microsimulation Model of the Health and Financial Effects of Parkinson’s Disease
Study Rationale: As new treatments for Parkinson's disease (PD) are developed, it is important to determine how they might affect the health and finances of people with PD, their families and society...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2024Development and Validation of a Sensitive Method for Measuring PRKN
Study Rationale: Mutations in the genes encoding PRKN and PINK1 are associated with Parkinson’s disease (PD). PINK1 and PPKN proteins work together to mediate the degradation of damaged mitochondria...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Clinical Trial to Investigate the Safety of Repeated Subcutaneous Injections of HER-096, a Novel Candidate for Disease-modifying Therapy in Parkinson’s Disease
Study Rationale: sHER-096 is a novel compound that mimics CDNF, a human neurotrophic factor that has shown neuroprotective and neurorestorative properties in an animal model of Parkinson’s disease (PD...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Therapeutic Development of Novel STING Inhibitors to Treat Parkinson's Disease Neuroinflammation
Study Rationale: Brain inflammation plays an important role in the pathology and progression of Parkinson’s disease (PD). One of the key proteins involved in this inflammatory process is STING...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Use of the Dual-action Neuroprotective Compound KLS-13019 to Treat Motor Impairment in a Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with a loss of mitochondrial function and increased inflammation. A dual-action drug candidate, KLS-13019, both protects mitochondria from...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.